Waldenström macroglobulinaemia: the key questions. Br J Haematol 2013 Aug;162(3):295-303
Date
05/09/2013Pubmed ID
23651417DOI
10.1111/bjh.12367Scopus ID
2-s2.0-84880275386 (requires institutional sign-in at Scopus site) 9 CitationsAbstract
In this review, the key issues that pertain to Waldenström disease are discussed in a concise question-and-answer format. Diagnosis, prognosis, and indications for state-of-the-art therapy are updated. Current therapies presented at the 7th International Workshop for Waldenström Macroglobulinaemia are included.
Author List
D'Souza A, Ansell S, Reeder C, Gertz MAAuthor
Anita D'Souza MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antineoplastic AgentsGenetic Predisposition to Disease
Hematopoietic Stem Cell Transplantation
Humans
Prognosis
Risk Factors
Waldenstrom Macroglobulinemia